Last updated on June 2019

A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable


Brief description of study

The purpose of this study is to determine the efficacy and safety of baricitinib in combination with topical corticosteroids in participants with moderate to severe atopic dermatitis who have experienced failure to cyclosporine or are intolerant to, or have contraindication to cyclosporine.

Clinical Study Identifier: NCT03428100

Find a site near you

Start Over

AKH

Wien, Austria
  Connect »

Hopital Larrey

Toulouse cedex 9, France
  Connect »

Praxis Rotterdam

Gelsenkirchen, Germany
  Connect »

Yanagihara dermatology clinic

Ainokawa, Ichikawa-shi, Japan
  Connect »

Fumimori Clinic

Fukuoka-shi, Japan
  Connect »

Noguchi Dermatology

Kashima-machi, Kamimashiki-gun, Japan
  Connect »

Kume Clinic

Nishi-ku Sakai-shi, Japan
  Connect »

Sanrui Dermatology Clinic

Ohmiya-ku,Saitama-shi, Japan
  Connect »

Bravis Ziekenhuis

Bergen op Zoom, Netherlands
  Connect »

LLC ArsVitae NorthWest

Saint-Petersburg, Russian Federation
  Connect »

LLC Medical Center "Kurator"

Saint-Petersburg, Russian Federation
  Connect »

SPb SBHI Skin-venerologic dispensary #10

St. Petersburg, Russian Federation
  Connect »

Hospital Universitari de Bellvitge

L'Hospitalet de Llobregat, Spain
  Connect »

Kantonsspital St. Gallen

St. Gallen, Switzerland
  Connect »

Broadgreen Hospital

Liverpool, United Kingdom
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.